Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

68° Partly Cloudy

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2026

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

459.81 -0.20 (-0.04%)

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗

January 12, 2024

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

Via Benzinga

3 Stocks That Could Be Monster Winners in 2024 ↗

December 30, 2023

Don't be surprised if these three stocks take off in the new year.

Via The Motley Fool

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 08, 2023

Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.

Via Benzinga

Analyst Ratings for Madrigal Pharmaceuticals ↗

November 13, 2023

Via Benzinga

2 Risky Stocks With Massive Potential ↗

October 17, 2023

Neither is doing well this year.

Via The Motley Fool

1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street ↗

September 20, 2023

This company is on the brink of a major breakthrough.

Via The Motley Fool

These 2 Stocks Could Be About to Soar: Are They Buys? ↗

December 07, 2023

One thing is for certain -- both of these companies are innovators.

Via The Motley Fool

Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗

November 30, 2023

These stocks just might have investors seeing double over the next few years.

Via The Motley Fool

Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? ↗

November 21, 2023

New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,...

Via Benzinga

Topics ETFs

Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating ↗

November 17, 2023

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Via Investor's Business Daily

The 3 Most Undervalued Biotech Stocks to Buy: November 2023 ↗

November 14, 2023

Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits.

Via InvestorPlace

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading

September 13, 2023

Via Investor Brand Network

The Latest Analyst Ratings for Madrigal Pharmaceuticals ↗

September 11, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 02, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 19, 2023

Via Benzinga

Nike, Carnival And 3 Stocks To Watch Heading Into Friday ↗

September 29, 2023

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today? ↗

September 28, 2023

U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28.

Via Benzinga

Topics Stocks

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. ↗

September 27, 2023

It has a good shot at commercializing a drug to treat a common liver disease.

Via The Motley Fool

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗

September 21, 2023

Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...

Via Benzinga

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line ↗

September 13, 2023

The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures.

Via Investor's Business Daily

Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday ↗

September 11, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to...

Via Benzinga

Topics Stocks

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of ↗

August 30, 2023

Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months.

Via InvestorPlace

The 3 Most Promising Pharma Stocks to Own Now ↗

August 30, 2023

A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.

Via InvestorPlace

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗

August 23, 2023

NASH treatments are projected to be one of the most sought-after indications in the coming years.

Via The Motley Fool

Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗

August 23, 2023

NASH is a surprisingly common ailment, and the first treatments are on the way.

Via The Motley Fool

Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy? ↗

August 02, 2023

Novo Nordisk received some good news in a recent physician survey.

Via The Motley Fool

Madrigal Stock Pops As It Makes Inroads Into What Could Be A $160 Billion Market ↗

June 30, 2023

Madrigal is working on gaining FDA approval for what could be the first NASH treatment.

Via Investor's Business Daily

Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗

June 28, 2023

Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was...

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: editor@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

Sections

Services

Follow Us